GlobeNewsWire
26 Aug 2026, 10:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
An FDA advisory committee voted 9-3 that available evidence does not support the efficacy of Capricor's lead product, Deramiocel, for treating DMD-associated cardiomyopathy. — A negative advisory panel vote on a lead product candidate is a critical failure that significantly diminishes the probability of FDA approval and future revenue.
-0.90The FDA raised concerns regarding post-hoc changes to the statistical analysis plan used for Deramiocel's primary endpoint shortly before data unblinding. — Allegations of data manipulation or unauthorized analysis changes undermine the integrity of the clinical results and invite regulatory rejection.
-0.70A securities fraud class action lawsuit has been filed against Capricor Therapeutics and its executives alleging misstatements regarding Deramiocel's clinical data. — Legal action adds financial liability and reputational risk, though the primary driver of price decline was the clinical failure.
-0.40Continue reading
6 related stories
Top 2 movers · tap to explore
The FDA previously issued a Complete Response Letter stating the Deramiocel application did not meet statutory requirements for substantial evidence of effectiveness. — This confirms existing regulatory hurdles and a lack of confidence from the FDA prior to the advisory meeting.
-0.30Which stocks this story touches
The company is facing a securities fraud class action lawsuit following a massive stock price drop and FDA concerns over clinical data integrity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
9h ago
